Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Drug Name | NG-641 |
| Trade Name | |
| Synonyms | NG 641|NG641 |
| Drug Descriptions |
NG-641 is an engineered oncolytic enadenotucirev adenovirus expressing a bispecific FAP-TAc T-cell activator that binds to fibroblast activating protein (FAP) on cancer associated fibroblasts and to CD3 on T-lymphocytes, as well as CXCL9, CXCL10, and IFN alpha, which potentially enhances T-cell activation and induces killing of FAP-positive tumor fibroblasts (Cancer Res 2019;79(13 Suppl):Abstract nr 5013). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C168790 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| NG-641 | NG-641 | 0 | 2 |
| NG-641 + Nivolumab | NG-641 Nivolumab | 0 | 1 |
| NG-641 + Pembrolizumab | NG-641 Pembrolizumab | 0 | 1 |
CKB BOOST